In the Press
December 31, 2018
Foreign Investment Control Interview with Christophe Digoy and Richard Matheny (Les Echos)
Professionals
Partners Richard Matheny sat down with Les Echos to discuss foreign investment control with regards to French, European and US regulations.
Watch the full video.
Related Content
- AlertMarch 27, 2026
FCC Expands Covered List to Include Foreign-Produced Routers
- AlertMarch 24, 2026
Small Business Innovation and Economic Security Act Will Bring Big Changes
- AlertMarch 17, 2026
White House Directs Agencies to Increase Scrutiny of “Made in America” Product Claims
- AlertMarch 5, 2026
Is Claude a Supply Chain Risk? What Federal Contractors Need to Know About This Designation
- InsightMarch 3, 2026
What the Supreme Court’s Tariff Decision Means for Presidential Power
- AlertFebruary 20, 2026
Supreme Court Strikes Down IEEPA Tariffs; Refund Process to Be Determined
- AlertFebruary 2, 2026
The 2026 National Defense Strategy Signals Increased DIB Contracting and Investment Opportunities
- AlertDecember 23, 2025
Final FY 2026 NDAA Includes BIOSECURE Act Provisions and New Opportunities for Biotech as DOD National Security Priority
- Awards and RankingsJune 10, 2026
The Legal 500 US 2026 Recognizes 47 Goodwin Practices and 185 Lawyers
- Awards and RankingsJune 4, 2026
Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service
- Awards and RankingsMay 14, 2026
Lawdragon Names 10 Goodwin Partners Among 500 Leading Global Cyber Lawyers
- Press ReleaseApril 1, 2026
Goodwin Advises Watlow and Tinicum on Privatization of Genes Tech
- WebinarFebruary 24, 2026
Tariffs at the Supreme Court: Key Takeaways and the Road Ahead
- Awards and RankingsFebruary 13, 2026
Goodwin Achieves Record Number of Rankings in Chambers Global 2026
- Press ReleaseJanuary 26, 2026
Flow Neuroscience Announces FDA Approval of World’s First At-Home Brain Stimulation Treatment for Depression
- Press ReleaseJanuary 13, 2026
Goodwin Advises SciNeuro in Entering into a Licensing and Collaboration Agreement with Novartis for $165 Million Upfront and Up to $1.5 Billion in Milestones